676 related articles for article (PubMed ID: 30813769)
21. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
22. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).
Garces F; Mohr C; Zhang L; Huang CS; Chen Q; King C; Xu C; Wang Z
Cell Rep; 2020 Feb; 30(6):1714-1723.e6. PubMed ID: 32049005
[TBL] [Abstract][Full Text] [Related]
23. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
[TBL] [Abstract][Full Text] [Related]
24. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
[TBL] [Abstract][Full Text] [Related]
25. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
[TBL] [Abstract][Full Text] [Related]
26. Erenumab efficacy in migraine headache prophylaxis: A systematic review.
Bagherzadeh-Fard M; Amin Yazdanifar M; Sadeghalvad M; Rezaei N
Int Immunopharmacol; 2023 Apr; 117():109366. PubMed ID: 37012858
[TBL] [Abstract][Full Text] [Related]
27. Timing and durability of response to erenumab in patients with episodic migraine.
McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
[TBL] [Abstract][Full Text] [Related]
28. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
29. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
Arca K; Reynolds J; Sands KA; Shiue HJ
Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
[No Abstract] [Full Text] [Related]
30. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
[TBL] [Abstract][Full Text] [Related]
31. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
32. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
33. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
[TBL] [Abstract][Full Text] [Related]
34. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
Ornello R; Casalena A; Frattale I; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
J Headache Pain; 2020 Apr; 21(1):32. PubMed ID: 32264820
[TBL] [Abstract][Full Text] [Related]
35. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.
Ohlsson L; Haanes KA; Kronvall E; Xu C; Snellman J; Edvinsson L
Cephalalgia; 2019 Dec; 39(14):1745-1752. PubMed ID: 31366221
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
[TBL] [Abstract][Full Text] [Related]
38. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
39. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
Suzuki K; Suzuki S; Fujita H; Sakuramoto H; Shioda M; Hirata K
Neuropsychopharmacol Rep; 2024 Jun; 44(2):482-484. PubMed ID: 38602109
[TBL] [Abstract][Full Text] [Related]
40. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.
de Hoon J; Van Hecken A; Vandermeulen C; Yan L; Smith B; Chen JS; Bautista E; Hamilton L; Waksman J; Vu T; Vargas G
Clin Pharmacol Ther; 2018 May; 103(5):815-825. PubMed ID: 28736918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]